Dossier · GSHD · Dormant
GSHD · Goosehead Insurance, Inc. · Stock research
Last analysed ·
Current thesis
Sell-side is re-rating GSHD ahead of the tape: five price-target raises in eight days (Piper $52→$72, Cantor $76, UBS $70, JPM $60, RBC $55) against a stock still at $54.28 and -49% YoY. The 2026-07-22 Q2 print is the binary that decides whether the analyst cluster is early or wrong — no edge entering into it.
Invalidation trigger
A weekly close below $47 breaks the base built off the $33.68 low and reopens the lows; secondarily, a Q2 print on 2026-07-22 that trims the 10–19% FY organic revenue-growth guide or shows new-business commissions decelerating from the +29% Q1 pace confirms the deceleration case.
Thesis status
Open commitment scored if the trigger above fires How this is scored →Latest analysis and events for GSHD —
As of 2026-07-29, orbyd's latest analysis for Goosehead Insurance, Inc. (GSHD): Sell-side is re-rating GSHD ahead of the tape: five price-target raises in eight days (Piper $52→$72, Cantor $76, UBS $70, JPM $60, RBC $55) against a stock still at $54.28 and -49% YoY. The 2026-07-22 Q2 print is the binary that decides whether the analyst cluster is early or wrong — no edge entering into it.
Invalidation trigger: A weekly close below $47 breaks the base built off the $33.68 low and reopens the lows; secondarily, a Q2 print on 2026-07-22 that trims the 10–19% FY organic revenue-growth guide or shows new-business commissions decelerating from the +29% Q1 pace confirms the deceleration case.
Current Thesis
Spot $54.28 (2026-07-17 close), inside a 52-week range of $33.68–$104.00, market cap $1.93B and down roughly 49% year-over-year. The stock has ground about 3% higher over the past two weeks while five brokers raised price targets in eight days — Piper Sandler $52→$72 on 2026-07-15, JP Morgan $55→$60 and RBC $52→$55 on 2026-07-13, Cantor Fitzgerald $67→$76 on 2026-07-09, UBS $67→$70 on 2026-07-08. Not one of those was a rating upgrade. Consensus targets now sit ~$66.83–68.73 against $54.28 spot, a ~23% implied gap the tape has declined to close. That gap is the whole setup: either the Q2 print on 2026-07-22 validates the target moves and the derate stops, or the marks get walked back. Entering a three-day-out binary on a name with no momentum cushion is a gamble on the print, and the analyst cluster arriving before the numbers is a reason to watch, not to size.
Bullish and bearish views on Goosehead Insurance, Inc.
The model's bull view on Goosehead Insurance, Inc. (GSHD), in brief: Q1 2026 (reported 2026-04-22): total revenue +23% YoY to $93.1M; core revenue +15% to $79.5M; total written premium +13% to $1.13B; policies in force +14% to ~1.97M. The bear view: The market cap is down 49% YoY and the 52-week high has rolled from $105.01 to $104.00 — the descending high is mechanical evidence the distribution phase from the peak is still the governing structure. Both cases follow in full.
Bull Case
- Q1 2026 (reported 2026-04-22): total revenue +23% YoY to $93.1M; core revenue +15% to $79.5M; total written premium +13% to $1.13B; policies in force +14% to ~1.97M.
- Adjusted EBITDA +57% to $24.4M in Q1 2026, margin to 26%. Net income tripled to $8.0M from $2.6M; diluted EPS $0.19. Operating leverage is showing up before revenue reaccelerates.
- New business commissions +29% in Q1 2026, described on the call as the fastest franchise pace in nearly five years — the leading indicator that matters more than the headline revenue line.
- Digital Agent 2.0 now runs automated quote-and-bind on home and auto. RBC cited the capability explicitly when it lifted its target on 2026-04-23, and it is the mechanism by which the FY guide's upper band gets hit.
- Multiple already reset: forward P/E ~25.3 against trailing ~50. The 2021–2024 premium is largely gone, so a re-rate no longer requires a heroic multiple.
- FY2026 guide reiterated at 10–19% organic total-revenue growth and 12–20% written-premium growth on a $382.2M TTM revenue base (+17.7%).
Bear Case
- The market cap is down 49% YoY and the 52-week high has rolled from $105.01 to $104.00 — the descending high is mechanical evidence the distribution phase from the peak is still the governing structure.
- Growth is decelerating against its own history: core revenue +15% and an FY band of 10–19% for a franchise that printed 30–40%+ in prior years. Multiples follow growth rates down, and that repricing may not be finished.
- RBC's own note trims 2026 quarterly estimates and models flat-to-down margins for the year, while saying it needs "clear acceleration" in digital-channel revenue before turning more positive. The target went up; the bar did not come down.
- TTM net income $30.4M is down 1.9% and EPS $1.09 is down 13.8% — the derate has fundamental support, not just sentiment.
- Q1 2026 franchise churn: 10 exits and 63 consolidations against 20 launches, with total producers up only 3% YoY. Productivity per franchise is carrying the growth, and that lever has a ceiling.
- The rating book stays split at roughly 7 Buy / 5 Hold / 2 Sell across 14 brokers, with a consensus recommendation of "Hold". Higher targets on unchanged ratings is a bookkeeping move, not accumulation.
Setup & Price Structure
The move from $33.68 into the mid-$50s is a mean-reversion leg off a washout that took the stock ~68% off its high, and it has stalled: $51.65 on 2026-07-15 inside a $50.19–$53.02 session range, $54.28 by 2026-07-17. Two weeks of PT raises bought roughly three percent of price. That divergence is the read — when sell-side marks move 38% (Piper) and the stock moves 3%, the marginal buyer is absent. The weekly chart still shows lower highs from $105.01 with no reclaimed prior base, and personal-lines distribution peers are not breaking out alongside it, so there is no cluster confirmation to lean on. What would qualify as a trend change is a higher low above the $47–48 shelf followed by a weekly close that takes out the June range high on expanding volume — a structure that does not exist yet and cannot exist before Wednesday.
Catalyst Calendar (next 30 days)
- Through 2026-08-18 — No scheduled investor conference or capital-markets event on the calendar. Between the 10-Q and the Q3 print there is no dated catalyst, which means the tape has to do the work unaided.
Elapsed catalysts
- 2026-07-22 (confirmed) — Q2 2026 results after the close, conference call 16:30 ET. The binary. Grade three things: whether the 10–19% FY organic revenue guide holds or narrows, whether new-business commissions sustain anything near the +29% Q1 pace, and whether management quantifies Digital Agent 2.0 channel revenue. (passed 18d ago)
- 2026-07-23 (est.) — Post-print analyst revision window. Five targets raised into the print means five marks to defend; a soft guide produces immediate walk-backs, and the $55–$60 targets (RBC, JPM) become the resistance the stock trades against. (passed 17d ago)
- ~2026-08-05 (est.) — Form 10-Q filing, roughly two weeks post-release. Watch producer count, franchise launches versus terminations, and contingent-commission contribution to the Q2 revenue beat. (passed 4d ago)
What Would Change Our Mind
- A Q2 print that raises or narrows the FY organic guide toward the 19% upper band, paired with a quantified Digital Agent 2.0 revenue contribution, converts this from a de-rated broker into an earnings-inflection setup worth a real entry on the post-print retest.
- A weekly close above $60 on volume — clearing the JPM target and the descending trend from $105.01 — would be the first structural evidence the downtrend is over rather than paused.
- Conversely, a weekly close below $47 breaks the base built off the $33.68 low and puts the lows back in play; the correct response is to stand aside, not to average into it.
- A guide cut on 2026-07-22, or new-business commission growth decelerating from +29% toward the low teens, confirms the deceleration bear case and makes the analyst target cluster a contrary indicator.
- Watch whether any of the five July target raises converts to an actual ratings upgrade post-print. Targets moving without ratings moving is noise; a Hold-to-Buy transition at JPM or RBC would be signal.
Correlation Notes
- Trades with personal-lines insurance distribution and small-cap insurance brokers rather than with underwriters — the P&C pricing cycle affects it second-order, through commission rates and contingent payouts, and Q1's contingent commissions were a visible swing factor in the +23% headline.
- Housing and auto transaction volume are the real upstream driver: policies in force grow when homes change hands. Mortgage-rate direction is a cleaner leading indicator for this name than the insurance tape is.
- Sensitive to the small-cap growth-versus-value rotation. In a risk-on small-cap tape the forward ~25x on a double-digit grower re-rates quickly; in a defensive tape the trailing ~50x and negative EPS growth is what gets marked.
- Theme classification has been unstable across recent scans — insurance-insurtech, specialty distribution, small-cap value, and unrelated buckets have all been assigned. That instability itself says the narrative is not clearly owned by any accelerating theme, which is consistent with the price action.
- Idiosyncratic risk dominates through 2026-07-22. No index or sector move is going to matter more than the guide language on Wednesday's call.
Notes
- UBS reiterated Buy but cut PT to $67 on 2026-06-09. Consensus targets ~$65–71, wide dispersion $43–$125, split rating book — no sell-side chase.
- Growth deceleration is the core bear thesis: core revenue +15% Q1 2026, FY guide 10–19% vs 30–40%+ in prior years. New-business commissions +29% Q1 is the offsetting bull data point to track.
- Earnings blackout: Q2 2026 prints after the close Wednesday 2026-07-22, call 16:30 ET. Three trading days out as of 2026-07-19 — binary risk, no fresh entries into the print.
- Analyst-cluster event (2026-07-08 to 2026-07-15): UBS $67→$70, Cantor $67→$76, RBC $52→$55, JPM $55→$60, Piper $52→$72. Five raises, zero rating upgrades — targets moved, conviction did not. Consensus PT ~$66.83–68.73 vs $54.28 spot.
- Rating book stays split: roughly 7 Buy / 5 Hold / 2 Sell across 14 brokers, consensus recommendation reads 'Hold'. Target dispersion remains wide.
- Price reconciliation (2026-07-17): spot $54.28, 52-wk range $33.68–$104.00 (the high has rolled down from $105.01). Market cap $1.93B, -49% YoY.
- RBC's stated bar (2026-04-23, Sector Perform): needs 'clear acceleration in revenues attributable to' the Digital Agent 2.0 channel to get more positive, and models flat-to-down 2026 margins. That is the specific number to grade on the Q2 call.
- Growth deceleration remains the core bear thesis: core revenue +15% Q1 2026, FY organic guide 10–19% vs 30–40%+ in prior years. New-business commissions +29% Q1 is the offsetting bull datapoint.
Related · shared themes
HUM
Humana Inc.
Post-print floor held: the 2026-08-05 undercut to $353.69 closed green on CVS's Aetna guide raise, and 2026-08-07 closed $385.00 (+4.84%), back above the 50-day of $374.23 and the highest close since 07-28. Morgan Stanley's 08-05 upgrade retired the $249 bear target, but the ≥3% 2028 MA margin claim stays unquantified for 2027 and no company-dated financial event is confirmed inside 30 days.
RXO
RXO, Inc.
Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground — bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to consensus; the ~2026-08-05 Q2 print (adj EBITDA guide $27–37M vs $6M Q1) is the binary the whole re-rate discounts.
CNC
Centene Corporation
Post-print recovery extended: $65.77 close on 2026-08-07 (+2.45%), above the 20-day and 50-day levels marked on 08-04, with the $69.36 52-week high in view. Two dated events inside four sessions — CMS's 3:00pm EDT 2026-08-12 PY2027 rate lock (HealthCare.gov states only; SBE states run to 10-15) and the 08-13 $500M par redemption. Theme still SATURATED: eight post-print target raises, zero cuts, consensus $71.67 scored at 8.97% upside.
HNGE
Hinge Health, Inc.
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.